Galaxia OLIGE Galaxia Olige (open Life Science Knowledge Graph Engine) - Europe’s First Explainable Ai Memory Infrastructure for Life Sciences
- Coordinator
- Smabbler Spolka Z Ograniczona Odpowiedzialnoscia, Poland
- Runs
- 1 July 2026 to 30 June 2027
- Status
- Running
- EU funding
- €499k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101310588
What the project is doing
In the project's own words, from its summary on CORDIS.
Galaxia OLIGE is a breakthrough project to establish Europe’s first Explainable AI Memory Infrastructure for Life Sciences - a sovereign, sustainable, and publicly accessible knowledge system that empowers regulators, researchers, pharmaceutical innovators, and health agencies with transparent, evidence-based intelligence. Galaxia OLIGE introduces a new class of AI infrastructure: a Hypergraph Language Model (HLM) that autonomously transforms unstructured biomedical text into a dynamic, explainable semantic memory layer.
Unlike LLMs, Galaxia does not generate probabilistic output; it performs traceable, deterministic reasoning. Unlike knowledge graphs, it requires no manual schema engineering and supports n-ary biomedical relationships at scale. It operates entirely in-memory on CPU infrastructure - making it energy-efficient, sovereign by design, and aligned with Europe’s Green Deal and digital autonomy goals. This EIC Pre-Accelerator project will advance Galaxia from Technology Readiness Level (TRL) 4-5 to TRL 6 by deploying the technology in a real-world life sciences environment.
Over 12 months, Galaxia OLIGE will integrate the OpenWebSearch.eu Open Web Index as a European data source, process over 200 million characters of scientific and regulatory content, and build the first Public Life Sciences Knowledge Graph for Europe, accessible via both a user-friendly interface and developer API.This platform will enable users to:1. Ask complex natural-language questions (e.g., drug-drug interactions, adverse events, dosage risks, regulatory constraints).2.
Receive deterministic, explainable results with full source provenance3. Trust AI outputs in compliance with the EU AI Act and EMA regulatory frameworks4. Integrate knowledge directly into pharmaceutical R&D, compliance systems, and innovation tools.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Smabbler Spolka Z Ograniczona Odpowiedzialnoscia | Zorawina | Poland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI